Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy.

@article{Despierre2013FolateRA,
  title={Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy.},
  author={Evelyn Despierre and Sandrina Lambrechts and Karin Leunen and Patrick Berteloot and Patrick Neven and Fr{\'e}d{\'e}ric Amant and Daniel J O'Shannessy and Elizabeth B. Somers and Ignace Vergote},
  journal={Gynecologic oncology},
  year={2013},
  volume={130 1},
  pages={192-9}
}
OBJECTIVE Based on its expression profile, folate receptor alpha (FRA) is an attractive candidate for targeted diagnostics and therapeutics. However, applicability of these agents in residual or recurrent disease could be influenced by chemotherapy. We evaluated whether chemotherapy modified FRA expression in non-mucinous epithelial ovarian (EOC) and endometrial carcinoma (EC). METHODS FRA staining was evaluated by immunohistochemistry, using MAb 26B3, in 81 patients (41 EOCs and 40 ECs) and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Similar Papers

Loading similar papers…